Biomarkers.

Background: As new anti-amyloid immunotherapies emerge for Alzheimer's disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P-tau217) for the detection of primary AD or AD co-pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.

Public Health.

Background: The IDEAL study is a randomized clinical trial investigating the psychosocial, behavioral, and cognitive impacts of genetic risk disclosure for late-onset Alzheimer's disease (LOAD) among Latinos.

Methods: We used address-based sampling in northern Manhattan to recruit Latinos aged 40-64 for a community-based survey and clinical trial. Data collection encompasses demographics, Alzheimer's disease (AD) family history, knowledge and beliefs about AD and genetics, current mental health status, acculturation, impact of COVID-19, familism, fatalism, caregiver status, and prior AD genetic testing.

Public Health.

Background: Shared genetic risk between Alzheimer's disease (AD) and concussion may help explain the association between concussion and elevated risk for dementia. However, there has been little investigation into whether AD risk genes also associate with concussion severity/recovery, and the limited findings are mixed. We used AD polygenic risk scores (PRS) and APOE genotypes to investigate associations between AD genetic risk and concussion severity/recovery in the NCAA-DoD Grand Alliance CARE Consortium (CARE) dataset.

Developing Topics.

Background: Minimally invasive diagnostic tools are crucial to characterize heterogeneous mild cognitive impairment (MCI), pre-MCI, and Alzheimer's disease (AD) cohorts. Our approach is based on targeted selection and quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma. Here, we report the comparative analysis of 24 microRNAs comprising CogniMIR panel in 200 plasma samples with our Gen1 and Gen2 software algorithms towards distinguishing cognitively unimpaired (CU), MCI and AD cohorts.

Managing cognitive impairment in Parkinson's disease: an update of the literature.

Introduction: Cognitive impairment in Parkinson's disease (PD) substantially affects patient outcomes, function, and quality of life. PD-related cognitive dysfunction is often heterogeneous in clinical presentation and rates of progression. As cognitive changes occur in many people with PD, it is essential to evaluate cognition, provide education, and implement management strategies for cognitive symptoms.